SRF Limited announced its consolidated financial results for the third quarter and nine months ended December 31, 2025. The Board of Directors approved these unaudited results in a meeting held on January 20, 2026.

Consolidated revenue for Q3FY26 increased by 6% to ₹3,713 crore from ₹3,491 crore in the corresponding period last year. Earnings Before Interest and Tax (EBIT) saw a significant rise of 23%, from ₹529 crore to ₹653 crore. Profit After Tax (PAT) surged by 60%, reaching ₹433 crore compared to ₹271 crore in the previous year.

Commenting on the performance, Chairman and Managing Director, Ashish Bharat Ram, stated, “On an overall basis, this has been a good quarter for the Company. Despite a very volatile environment, we have been able to generate a reasonable growth in revenue along with a much-improved bottom line. We remain cautiously optimistic about the future.”

The Board also approved a second interim dividend of ₹5 per share. This follows the first interim dividend of ₹4 per share approved on July 23, 2025.

Segment-wise, the Chemicals Business reported a 22% increase in revenue to ₹1,825 crore and a 36% rise in operating profit to ₹496 crore. The Fluorochemicals Business performed exceptionally well due to strong refrigerant gas performance. The Specialty Chemicals Business experienced muted performance owing to aggressive Chinese pricing and deferred customer offtake, but is strengthening its long-term foundation.

The Performance Films & Foil Business saw a 3% decline in revenue to ₹1,342 crore, though operating profit increased by 5% to ₹95 crore. This segment faced temporary disruptions but is showing signs of recovery.

The Technical Textiles Business reported an 11% decrease in revenue to ₹454 crore and a 24% drop in operating profit to ₹45 crore, impacted by pricing pressures and reduced exports.

Other Businesses experienced a 9% revenue decline to ₹92 crore, with operating profit increasing by 8% to ₹17 crore.

For the first nine months of FY26, SRF’s revenue grew 8% to ₹11,171 crore, and PAT increased by 73% to ₹1,253 crore.

An additional gratuity and leave liability of ₹73 crore was recognized due to the implementation of new Labour Codes.

The Board approved the establishment of a new Pharma Intermediates Plant at Dahej with an investment of ₹180 crore.

As of December 31, 2025, SRF has applied for 506 patents, with 153 granted globally.